Author

A. Kupke

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2 Microbiology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:host-pathogen & immune response· 4 Approach:experimental assay· 3 Research Focus:drug response / drug discovery· 2 Organism:mouse· 2 Assay:proteomics· 2 Assay:bulk RNA-seq· 1 Organism:human· 1 Assay:imaging· 1

Frequent Co-Authors

C. Rohde· 3 shared S. Becker· 3 shared S. Halwe· 3 shared A. Werner· 2 shared C. Kreer· 2 shared C. Wendtner· 2 shared F. Klein· 2 shared H. Gruell· 2 shared

Activity by Year

2020-2021 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersMicrobiology

C. Rohde

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

In contrast to TH2-biased approaches, TH1 COVID-19 vaccines protect Syrian hamsters from severe disease in the absence of dexamethasone-treatable vaccine-associated enhanced respiratory pathology

A. Ebenig, S. Muraleedharan, J. Kazmierski, D. Todt, A. Auste, M. Anzaghe, A. Gömer, D. Postmus, P. Gogesch, M. Niles, R. Plesker, C. Miskey, M. Gellhorn Serra, A. Breithaupt, C. Hörner, , M. D. Mühlebach

This study compares TH1 and TH2-biased vaccines in Syrian hamsters, showing that TH1 vaccines prevent severe disease without inducing VAERD, while TH2 vaccines cause VAERD through eosinophil recruitment and TH2 cytokine upregulation.

bioRxiv · Dec 28, 2021 · PreprintImmunology

Intranasal administration of a monoclonal neutralizing antibody protects mice against SARS-CoV-2 infection

S. Halwe, A. Kupke, K. Vanshylla, F. Liberta, H. Gruell, M. Zehner, C. Rohde, V. Kraehling, M. Gellhorn-Serra, C. Kreer, M. Kluever, L. Sauerhering, J. Schmidt, Z. Cai, F. Han, , S. Becker

This paper describes a monoclonal antibody, DZIF-10c, that effectively neutralizes SARS-CoV-2 and its variants when administered intranasally to mice, offering potential for topical treatment.

bioRxiv · Jun 9, 2021Microbiology

Immunogenicity and efficacy of the COVID-19 candidate vector vaccine MVA SARS 2 S in preclinical vaccination

A. Tscherne, J. H. Schwarz, C. Rohde, A. Kupke, G. Kalodimou, L. Limpinsel, N. M. A. Okba, B. Bosnjak, I. Sandrock, S. Halwe, L. Sauerhering, K. Printz, L. Nan, E. Duell, S. Jany, , A. Volz

This paper describes the preclinical evaluation of MVA-SARS-2-S, a vector vaccine against SARS-CoV-2, showing it induces immune responses and protects mice from infection.

bioRxiv · Jan 9, 2021Microbiology

Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients

C. Kreer, M. Zehner, T. Weber, C. Rohde, S. Halwe, M. S. Ercanoglu, L. Gieselmann, M. Korenkov, H. Gruell, P. Schommers, K. Vanshylla, V. Di Cristanziano, H. Janicki, R. Brinker, A. Ashurov, , F. Klein

This study isolates potent SARS-CoV-2-neutralizing antibodies from COVID-19 patients as early as 8 days post-diagnosis and identifies precursor B cells in healthy individuals.

bioRxiv · Jun 12, 2020Immunology